CN103393652A - Application of Sarcaboside A to medicament for treatment of laryngocarcinoma - Google Patents
Application of Sarcaboside A to medicament for treatment of laryngocarcinoma Download PDFInfo
- Publication number
- CN103393652A CN103393652A CN2013102642431A CN201310264243A CN103393652A CN 103393652 A CN103393652 A CN 103393652A CN 2013102642431 A CN2013102642431 A CN 2013102642431A CN 201310264243 A CN201310264243 A CN 201310264243A CN 103393652 A CN103393652 A CN 103393652A
- Authority
- CN
- China
- Prior art keywords
- sarcaboside
- laryngocarcinoma
- application
- preparation
- medicaments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of Sarcaboside A to preparation of medicaments for treatment of laryngocarcinoma and belongs to the technical field of novel application of medicaments. Through in vitro MTT antineoplastic activity evaluation, it is discovered that Sarcaboside A has substantial inhibition effect on growth of human laryngocarcinoma cell strains HEP-2, TU686, M2e and M4e. Accordingly, the Sarcaboside A can be applied to preparation of medicaments for resisting laryngocarcinoma and has good development and application prospects. The application of Sarcaboside A to preparation of medicaments for treatment of laryngocarcinoma involved in the invention is disclosed for the first time. The Sarcaboside A has a novel skeleton type and unimaginably strong activity in inhibition of laryngocarcinoma cells.
Description
Technical field
The present invention relates to the new purposes of compound S arcaboside A, relate in particular to the application of Sarcaboside A in the anti-laryngeal carcinoma medicine of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, having 74% to be the natural product or derivatives thereof, is exactly the reasonable antitumor drug of effect clinically at present as paclitaxel and derivant thereof.Therefore, from searching anticancer compound or lead compound natural product, have great importance.
the compound S arcaboside A that the present invention relates to is one and delivered (Li in 2012, X. et al., 2012. Two New-Skeleton Compounds from Sarcandra glabra. Helvetica Chimica Acta 95 (6), 998-1002.) New skeleton compound, this compound has brand-new framework types, there is no at present the report about activity, for the purposes in preparation treatment laryngeal carcinoma medicine that the present invention relates to, belong to open first, and because framework types belongs to brand-new framework types, there do not is the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control for laryngeal carcinoma simultaneously obviously has significant progress.
Summary of the invention
The invention provides the application of compound S arcaboside A in preparing antitumor drug.
The present invention adopts following technical scheme: the application of Sarcaboside A in the anti-laryngeal carcinoma medicine of preparation, and the structural formula of Sarcaboside A is as shown in formula I:
Formula I
The present invention finds by external MTT anti-tumor activity evaluation, and Sarcaboside A also has significant inhibitory action to the growth of people's laryngeal cancer cell strain HEP-2, TU 686, M2e and M4e, suppresses the IC of this 4 strain Growth of Cells
50Value is respectively 1.74 ± 0.35 μ M, 1.77 ± 0.32 μ M, 1.72 ± 0.33 μ M and 3.54 ± 0.45 μ M.Therefore, Sarcaboside A can, for the preparation of anti-laryngeal carcinoma medicine, have good development prospect.
The purposes of the Sarcaboside A that the present invention relates in preparation treatment carcinoma of tongue medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for Human Tongue Carcinoma Lines is active unexpectedly strong, there do not is the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control for carcinoma of tongue simultaneously obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The preparation method of compound S arcaboside A involved in the present invention is referring to document (Li, X. et al., 2012. Two New-Skeleton Compounds from Sarcandra glabra. Helvetica Chimica Acta 95 (6), 998-1002.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound S arcaboside A tablet involved in the present invention:
Get 20 and digest compound Sarcaboside A, add conventional adjuvant 180 grams that prepare tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound S arcaboside A capsule involved in the present invention:
Get 20 and digest compound Sarcaboside A, add the conventional adjuvant such as starch 180 grams that prepare capsule, mix, encapsulatedly make 1000.
Below by pharmacodynamic experiment, further illustrate its pharmaceutically active.
Experimental example: adopt the growth inhibited effect of mtt assay assessing compound Sarcaboside A to the strain of people's laryngeal cancer cell
1. method: the cell that is in the growth logarithmic (log) phase: people's laryngeal cancer cell strain HEP-2, TU 686, M2e and M4e(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.After cell culture 24 h are adherent, suck original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Sarcaboside A of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then along culture fluid top, suck 100 μ L supernatants, add 100 μ L DMSO, 10 min are placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating the cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Sarcaboside A has significant inhibitory action to the growth of people's laryngeal cancer cell strain HEP-2, TU 686, M2e and M4e.This compound suppresses the IC of people's laryngeal cancer cell strain HEP-2, TU 686, M2e and M4e growth
50Value is respectively: 1.74 ± 0.35 μ M, 1.77 ± 0.32 μ M, 1.72 ± 0.33 μ M and 3.54 ± 0.45 μ M.
By above-described embodiment, shown, Sarcaboside A of the present invention has good inhibitory action to the growth of people's laryngeal cancer cell strain HEP-2, TU 686, M2e and M4e.Prove thus, Sarcaboside A of the present invention has anti-laryngeal carcinoma activity, can be for the preparation of anti-laryngeal carcinoma medicine.
Claims (1)
1.Sarcaboside the application of A in treatment laryngeal carcinoma medicine, described compound S arcaboside A structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102642431A CN103393652A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside A to medicament for treatment of laryngocarcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102642431A CN103393652A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside A to medicament for treatment of laryngocarcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103393652A true CN103393652A (en) | 2013-11-20 |
Family
ID=49557513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013102642431A Pending CN103393652A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside A to medicament for treatment of laryngocarcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103393652A (en) |
-
2013
- 2013-06-27 CN CN2013102642431A patent/CN103393652A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861071B (en) | Application of Houttuynoid A in medicine for treating gastric cancer | |
| CN103405418A (en) | Application of Chukrasone B in medicine for treating breast cancer | |
| CN103393652A (en) | Application of Sarcaboside A to medicament for treatment of laryngocarcinoma | |
| CN103393645A (en) | Application of Sarcaboside B to medicament for treatment of skin cancer | |
| CN103393668A (en) | Application of Sarcaboside B to medicament for treatment of pancreas cancer | |
| CN103393658A (en) | Application of Sarcaboside A to medicament for treatment of bladder cancer | |
| CN103356550A (en) | Application of Sarcaboside B in medicine used for treating laryngeal cancer | |
| CN103393644A (en) | Application of Sarcaboside A to preparation of medicament for treatment of ileocecum cancer | |
| CN103393665A (en) | Application of Sarcaboside A to medicament for treatment of renal carcinoma | |
| CN103393653A (en) | Application of Sarcaboside B to medicament for treatment of carcinoma of bile duct | |
| CN103393654A (en) | Application of Sarcaboside A to medicament for treatment of endometrial carcinoma | |
| CN103356541A (en) | Application of Sarcaboside B in medicine used for treating gastric cancer | |
| CN103356532A (en) | Application of Sarcaboside B in medicine used for treating breast cancer | |
| CN103371996A (en) | Application of Sarcaboside A in medicine for treating nasopharynx cancer | |
| CN103356553A (en) | Application of Sarcaboside A in preparation of drug for treating breast cancer | |
| CN103356531A (en) | Application of Sarcaboside B in medicine used for treating cervical cancer | |
| CN103356589A (en) | Application of Sarcaboside A in preparation of drug for treating cervical cancer | |
| CN103356545A (en) | Application of Sarcaboside B in medicine used for treating ovarian cancer | |
| CN103356547A (en) | Application of Sarcaboside A in preparation of drug for treating skin cancer | |
| CN103446091A (en) | Application of Incarviatone A in laryngeal cancer treatment drug | |
| CN103356560A (en) | Application of Sarcaboside B in medicine used for treating prostate cancer | |
| CN103356577A (en) | Application of Sarcaboside A in preparation of drug for treating stomach cancer | |
| CN103356534A (en) | Application of Sarcaboside B in medicine used for treating colorectal cancer | |
| CN103463027A (en) | Application of Lycojaponicumin A in medicine for treating laryngocarcinoma | |
| CN103405412A (en) | Application of Chukrasone B in medicine for treating laryngocarcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131120 |